胎头娩出速度控制助产防护产妇会阴裂伤的价值

Value of speed control midwifery fetal head protection for maternal perineal laceration

目的探讨控制胎头娩出速度助产法在减少产妇会阴裂伤中的价值。方法选择2012年1月至2014年10月行阴道分娩的120例产妇为研究对象,随机将其分为对照组与研究组,每组60例,对照组产妇给予常规阴道助产保护,研究组产妇给予胎头娩出速度控制助产,比较两组会阴裂伤发生率及其裂伤程度、第二产程时间、产后出血量、住院时间。结果研究组会阴裂伤发生率、Ⅱ度裂伤率分别为18.33%、3.33%,对照组分别为40.00%、24.33%,两组比较比较差异有统计学意义(P<0.05)。产后出血量、住院时间研究组分别为(127.60±47.28)ml、(2.40±0.33)d,对照组分别为(179.52±89.35)ml、(3.43±0.62)d,两组比较差异均有统计学意义(P<0.05)。结论控制胎头娩出速度助产能明显减少产妇会阴裂伤发生率,减轻裂伤程度,缩短住院时间,值得临床推广。

Objective To investigate the value of speed control midwifery fetal head protection for maternal perineal laceration. Methods From January 2012 to October 2014,one hundrad and twenty patients with vaginal delivery were selected as the research objects,and they were randomly divided into control group and study group with 60 cases in each group. The control group was given the midwifery of routine vaginal maternal protection,and the study group was given the midwifery of controlling the speed of fetal head. The incidence of perineal laceration,the degree of laceration,the second delivery process,the postpartum blood loss and the length of hospital stay were compared between the two groups. Results The incidence of perineal laceration and degree Ⅱ laceration rate of the observation group were 18. 33% and 3. 33% respectively,and 40. 00% and 24. 33% in the control group,the differences had statistically significant between the two groups（ P〈0. 05）. In addition,the postpartum blood loss and the length of hospital stay of the observation group respectively were（ 127. 60 ± 47. 28） ml and（ 2. 40 ± 0. 33） d,the postpartum blood loss and the length of hospital stay of the control group respectively were（ 179. 52 ± 89. 35） ml and（ 3. 43 ±0. 62） d,and the differences had statistically significant between the two groups（ P〈0. 05）. Conclusion The midwifery of controlling the speed of fetal head can reduce the incidence of maternal perineal laceration,and alleviate the degree of laceration and shorten the hospital stay,so it is worthy of clinical promoted application.